Products and
Pipeline

Overview¹

- TAK-605 (TBio-6517; RIVAL-01) is a candidate from Turnstone Biologic’s oncolytic vaccinia virus platform, engineered for enhanced immune-stimulation and tumor cell selectivity, potent oncolysis and large transgene carrying capacity

- Turnstone and Takeda will co-develop and co-commercialize TAK-605 (TBio-6517; RIVAL-01) under a 50:50 global profit share

MOA²

TAK-605 (TBio-6517; RIVAL-01) consists of the vaccinia virus backbone encoding transgenes for FIt3 ligand, anti-CTLA-4 antibody and IL-12 p35 cytokine

Clinical Trials

Study Name

A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered by Intratumoral Injection, Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

References

1. Turnstone Biologics Press Release.

2. Takeda, Data on file.

Disclaimers

*In collaboration with Turnstone Biologics.